Low density lipoprotein catabolism is enhanced by the cleaved form of alpha-1-antitrypsin

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 57, Issue 4, 1997, Pages 325-335

  Janciauskiene, S ^a   Al Rayyes, O ^a   Floren, C H ^a   Eriksson, S ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alpha 1 antitrypsin; Cholesterol LDL receptor; Inflammatory processes; Serpin

Indexed keywords

ALPHA 1 ANTITRYPSIN; LOW DENSITY LIPOPROTEIN; SERINE PROTEINASE INHIBITOR;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; ISOELECTRIC FOCUSING; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL; PROTEIN ANALYSIS;

EID: 0030836051     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365519709099406     Document Type: Article

References (31)

1. Potempa J, Korzus E, Travis J. The serpin super-family of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269: 15957-60.
2. Bode W, Huber R. Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem 1992; 204: 433-51.
3. Mornex JF, Chytil-Weir A, Martinet Y, Courtney M, LeCocq JP, Crystal RG. Expression of the alpha-1-antitrypsin gene in mononuclear phagocytes of normal and alpha-1-antitrypsin-deficient individuals. J Clin Invest 1986; 77: 1952-61.
4. Stein PE, Carrell RW. What do dysfunctional serpins tell us about molecular mobility and disease? Nat Struct Biol 1995; 2: 96-113.
5. Carrell R, Travis J. Alpha-1-antitrypsin and the serpins: variation and countervariation. Trends Biochem Sci 1985; 10: 20-4.
6. Kalsheker NA. Molecular pathology of alpha-1-antitrypsin deficiency and its significance to clinical medicine. Q J Med 1994; 84: 653-8.
7. Wright HT, Scarsdale JN. Structural basis for the serpin inhibitor activity. Proteins: structure, function, and genetics. 1995; 22: 210-25.
8. Mast AE, Enghild JJ, Pizzo SV, Salvesen G. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha-1-proteinase inhibitor, alpha-1-anticymotrypsin, antitrombin III, alpha-2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry 1991; 30: 1723-30.
9. Lawrence DA, Olson ST, Palaniappan S, Ginsburg D. Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition. J Biol Chem 1994; 269: 27657-62.
10. Perlmutter DH, Glover GI, Rivetna M, Schasteen CS, Fallon RJ. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci 1990; 87: 3753-7.
11. Pratt CW, Church FC, Pizzo SV. In vivo catabolism of heparin cofactor II and its complex with thrombin: evidence for a common receptor-mediated clearance pathway for three serine proteinase inhibitors. Arch Biochem Biophys 1988; 262: 111-17.
12. Kounnas MZ, Church FC, Argraves WS, Strickland DK. Cellular internalization and degradation of antithrombin III-thrombin, heparin cofactor II-thrombin, and alpha-1-antitrypsin-trypsin complexes is mediated by the low density lipoprotein receptor-related protein. J Biol Chem 1996; 271: 6523-9.
13. Herz J, Goldstein JL, Strickland DK, Ho KY, Brown MS. 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/alpha-2-macroglobulin receptor. J Biol Chem 1991; 266: 21232-8.
14. Moestrup SK, Gliemann J, Pallesen G. Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res 1992; 269: 375-82.
15. Krieger M, Herz J. Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP). Annu Rev Biochem 1994; 63: 601-37.
16. Slunga L, Johnson O, Dahlen GH, Eriksson S. Lipoprotein (a) and acute-phase proteins in acute myocardial infarction. Scand J Clin Lab Invest 1992; 52: 95-101.
17. Vitols S, Björkholm M, Gahrton G, Peterson C. Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein receptor activity in tumor cells: evidence from studies in patients with leukaemia. Lancet 1985: 1150-3.
18. Galloway MJ, Mackie MJ, McVerry BA. Elastase-alpha-1-antitrypsin complexes in acute leukaemia. Thromb Res 1985; 38: 311-20.
19. Joslin G, Griffin GL, August AM, Adams S, Fallon RJ, Perlmutter DH. The serpin-enzyme complex (SEC) receptor mediates the neutrophil chemotactic effect of alpha-1-antitrypsin-elastase complexes and amyloid β peptide. J Clin Invest 1992; 90: 1150-4.
20. Dangler R, Lottspeich F, Oberthur W, Mast AE, Emmerich B. Limited proteolysis of alpha-1-proteinase inhibitor (alpha 1-PI) in acute leukemia: studies on the resulting fragments and implication for the structure of the inactivated inhibitor. Biol Chem Hoppe Seyler 1995; 376: 165-72.
21. Franzblau A, Criqui MH. Characteristics of persons with marked hypocholesterolemia. A population-based study. J Chronic Dis 1984; 37: 387-95.
22. Stefansson S, Lawrence DA, Argraves WS. Plasminogen activator inhibitor-1 and vitronectin promote the cellular clearance of thrombin by low density lipoprotein receptor-related proteins 1 and 2. J Biol Chem 1996; 271: 8215-20.
23. Janciauskiene S, Eriksson S. In vitro complex formation between cholesterol and alpha-1-proteinase inhibitor. FEBS Lett 1992; 316: 269-72.
24. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 1345-53.
25. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very-low-density lipoproteins. I Preliminary in vitro and in vivo observations. Biochim Biophys Acta 1972; 269: 212-21.
26. Salter AM, Saxton J, Brindley D. Characterization of the binding of human low-density lipoprotein to primary monolayer cultures of rat hepatocytes. Biochem J 1986; 240: 549-57.
27. Bierman RL, Stein O, Stein Y. Lipoprotein uptake and metabolism by aortic smooth muscle cells in tissue culture. Circ Res 1974; 35: 136-50.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with folin phenol reagents. J Biol Chem 1951; 193: 265-75.
29. Norusis MJ. SPSS for Windows, rel. 6.0. Chicago: SPSS, 1993.
30. Kovacs T, Kalapos MP, Mandl J, Spolarics Z, Garzo T, Antoni F, et al. Interaction of thrombin, antithrombin III and their complex with hepatocytes: comparison of the molecular components of human and mouse origin. Thromb Res 1987; 46: 875-80.
31. Fuchs HE, Shifman MA, Michalopoulos G, Pizzo SV. Hepatocyte receptors for antithrombin III-proteinase complexes. J Cell Biochem 1984; 24: 197-206.